Paper Details

  1. Home
  2. Paper Details

Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma.

Author: AtkinsM B, FinkK I, FisherR I, GucalpR, LouieA, MargolinK A, MierJ W, RubinsteinL, SparanoJ, WeissG R

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

Both IL-2 and IL-2/IFN therapy have activity in metastatic renal cell carcinoma. In particular, therapy with high-dose IL-2 alone produces meaningful and durable responses with manageable and reversible toxicity.
Paper Details　
Original Abstract of the Article :
PURPOSE: To determine better the activity of high-dose interleukin-2 (IL-2) either alone or in combination with interferon alfa-2b (IFN; Schering-Plough, Kenilworth, NJ) in patients with metastatic renal cell carcinoma, the IL-2 Working Group initiated a randomized phase II trial. PATIENTS AND METH...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.1993.11.4.661

データ提供：米国国立医学図書館（NLM）

High-Dose Interleukin-2: A Promising Treatment for Advanced Renal Cell Carcinoma

The fight against [cancer] is a continuous battle, with researchers constantly searching for new and effective treatments. This research focuses on the use of [high-dose interleukin-2 (IL-2)] in patients with [metastatic renal cell carcinoma]. Imagine this as a desert war against a formidable enemy, where IL-2 acts as a powerful weapon, targeting the cancer cells.

The study used a [randomized phase II trial] design to compare the efficacy of [IL-2] alone and in combination with [interferon alfa-2b (IFN)] in patients with [advanced renal cell carcinoma]. This research is like comparing the effectiveness of different battle strategies, testing which approach yields the best results.

A Powerful Weapon Against Cancer

The study found that [high-dose IL-2] showed significant activity against [metastatic renal cell carcinoma], producing meaningful and durable responses. This finding suggests that [IL-2] could be a valuable weapon in the arsenal against this challenging type of cancer.

Hope for Patients

This research offers hope for patients battling [advanced renal cell carcinoma]. The results of this study suggest that [IL-2] might be a powerful tool in the fight against this cancer, potentially leading to better outcomes and improved survival rates.

Dr. Camel's Conclusion

This research is like a victorious battle cry in the desert of cancer research. It shows the potential of high-dose IL-2 to effectively combat advanced renal cell carcinoma. This knowledge is like a powerful weapon in our arsenal, offering hope and new possibilities for patients facing this challenging disease.

Date :
  1. Date Completed 1993-05-24
  2. Date Revised 2020-12-26
Further Info :

Pubmed ID

8478661

DOI: Digital Object Identifier

10.1200/JCO.1993.11.4.661

Related Literature

Article Analysis
・Side Effects of interferon alfa-2b injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.